Skip to content
Recall Observatory FDA recall evidence

Exact FDA event identifier

Event 99237

1 recalled-product record grouped only because every row carries this exact official event ID.

Open FDA event record

Event summary

Timeline bucket
June 12, 2026
Product types
Drug
Classifications
Class II
Statuses
Ongoing
Recalling firm wording
Par Health USA, LLC

Dossier provenance

Source snapshots represented here

  • openFDA Drug Enforcement Report-date coverage June 20, 2012–July 08, 2026 Known gap: openFDA describes 2004-present coverage, but the current export has no report-date records in this interval.

Enforcement coverage uses report dates; product initiation dates can precede those bounds. Device-enrichment coverage uses FDA event_date_initiated.

How coverage and grouping work

Complete imported group

Every recalled product in this event

1 official enforcement rows

Product dates, classifications, firms, and source wording remain attached to their individual rows. Opening this dossier never hides products that did not match a prior timeline filter.

drug · product 1 of 1

Buprenorphine HCl, CIII, Injection, 0.3 mg/mL, 5 x 1 mL Single Dose Vials per Carton, Rx Only, For Intramuscular or Intravenous use, Manufactured for: Endo USA, Malvern, PA 19355, NDC 42023-179-05

D-0596-2026
Recall number
D-0596-2026
Initiated
June 12, 2026
Classification
Class II
Status
Ongoing
Recalling firm
Par Health USA, LLC
Quantity
46,334 units

App-derived interpretation

Unknown reason.no_named_rule · v1.0.0
Crystallization; identified as Buprenorphine free base

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Crystallization; identified as Buprenorphine free base

Code information

Lot #: 82886, exp 09/30/2026; 89646, exp 05/31/2027

Distribution pattern

Nationwide in the USA.